Key result
The editorial discusses the potential benefits of simultaneous platelet P2Y12 and P2Y1 ADP receptor blockade compared to selective P2Y12 blockade in acute coronary syndrome or PCI.
Why the study?
Does simultaneous platelet P2Y12 and P2Y1 ADP receptor blockade improve outcomes compared to P2Y12 blockade alone in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Does simultaneous platelet P2Y12 and P2Y1 ADP receptor blockade improve outcomes compared to P2Y12 blockade alone in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This editorial discusses the potential therapeutic role and rationale for simultaneous P2Y12 and P2Y1 receptor blockade in patients with acute coronary syndrome or undergoing percutaneous coronary intervention.
H uman platelets possess 3 purinergic receptors (P2Y 12 , P2Y 1 , and P2X 1 ), which collectively orchestrate key steps leading to platelet activation and aggregation (Figure).Until now, the selective blockade of the platelet P2Y 12 ADP receptor, combined with the inhibition of thromboxane production by aspirin, has remained the backbone of pharmacotherapy for patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention.1 Simultaneous Platelet P2Y 12 and P2Y 1 ADP Receptor BlockadeAre Two Better Than One?
No takes yet. Share an insight, caveat, or question.
Vaduganathan et al. (2016) conducted an editorial in Acute coronary syndrome or percutaneous coronary intervention. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade vs. Selective blockade of the platelet P2Y12 ADP receptor combined with aspirin was evaluated. The editorial discusses the potential benefits of simultaneous platelet P2Y12 and P2Y1 ADP receptor blockade compared to selective P2Y12 blockade in acute coronary syndrome or PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: